Responses
Regular and Young Investigator Award Abstracts
Novel Single-Agent Immunotherapies
1368 A novel bispecific BCA356 targeting tumour antigen CAIX conjugated to an attenuated IL12 demonstrates pre-clinical efficacy with potential for limited systemic toxicity
Compose a Response to This Article
Other responses
No responses have been published for this article.